NCT06747000|RecruitingDMC
Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders
Lipoprotein Functions in Healthy Individuals and Subjects With Lipid Disorders
Loading search results
Lipoprotein Functions in Healthy Individuals and Subjects With Lipid Disorders
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Departmental
observational
80
1 country
2
Study Start
July 18, 2024
Actual (reported)Primary Completion
July 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 18, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study looks at how lipoproteins, which are particles in the blood that transport cholesterol, influence heart and blood vessel health. Beyond just their levels, the way these particles function plays a key role in preventing or contributing to disease. In some conditions, like high cholesterol or diabetes, lipoproteins may not work properly, increasing the risk of clogged arteries and other complications. The investigators aim to study these changes in people with lipid disorders to better understand their impact on blood health and to find new ways to prevent and treat heart disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 18, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 18, 2024
Actual (reported)December 18, 2024
Actual (reported)December 24, 2024
Actual (reported)July 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 18, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percentage of platelet aggregation
Platelet aggregation area under the curve will be used as primary endpoint. Specifically, the percentage of platelet aggregation multiple time will be calculated to get area under the curve as a comprehensive marker for platelet aggregation response.
5 years
Percentage of Activated Platelets as Assessed by Flow Cytometry
5 years
Plasma levels of CRP in mg/L
5 years
Plasma levels of resolvins in pg/mL
5 years
Plasma Levels of IL-6 in pg/mL
5 years
Plasma Levels of TNF-α in pg/mL
5 years
Individuals with lipid disorders (elevated HDL and LDL)
Healthy individuals with normal lipid values and without lipid-related diseases
We Planning to start recruiting process in July 2024. We will identify potential subjects who are seen in the lipid clinic of Lifespan hospitals by EMR review. We will contact potential subjects at a routine care lipid clinic visit or by phone independent of their routine care visits. Recruitment will take place at the Lipid Clinic at Lifespan Hospital, the Brown campus, and our research lab.
Brown University Health Lipid Clinic
East Providence, Rhode Island, 02914, United States
Cardiovascular Research Center
Providence, Rhode Island, 02903, United States
Blood samples
First Submitted
December 18, 2024
First Posted
December 24, 2024
Study Start
July 18, 2024
Actual (reported)Primary Completion
July 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
July 18, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 1, 2025
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: